Trial of Lycopene/Ateronon for Secondary Prevention of Coronary Heart Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

213 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Ateronon, a nutritional supplement that contains lycopene from tomatoes has a favorable effect on carotid atherosclerosis, lipid levels, and other biomarkers of coronary heart disease.

The trial was stopped early due to insufficient financial support from the initial study collaborator, Cambridge Theranostics Ltd. Collected patient data are sufficient for final trial-based analyses to be conducted with financial support from the new study collaborator, CamNutra Ltd. The data will still be analyzed according to the original study aims.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TomVasc - Vascular Effects of Tomato Extract

NCT01100385

Ischemic Heart Disease Transient Ischemic Attack Stroke +1 more

COMPLETED NA

Lycopene in Preventing Prostate Cancer in Healthy Participants

NCT00322114

Prostate Cancer

UNKNOWN NA

Lycopene in Preventing Prostate Cancer in Patients Who Are at High Risk of Developing Prostate Cancer

NCT00416325

Prostate Cancer

COMPLETED PHASE1

Bioavailability of Carotenoids Added Into Processed Foods

NCT02246985

Cardiovascular Disease

COMPLETED NA

Lycopene in Healthy Male Participants

NCT00450957

Healthy, no Evidence of Disease Prostate Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lycopene, a carotenoid mainly found in tomato-based food products, has strong antioxidant properties relative to other carotenoids and has been postulated to play a role in the prevention of coronary heart disease through a variety of mechanisms. Lycopene cooked and consumed in oil mediums is optimal for not only its efficient absorption, but also its potential clinical effectiveness. Studies have also linked serum lycopene with the early stages of atherosclerosis, as measured by carotid artery intima-media thickness (IMT), a noninvasive ultrasound examination of the carotid arteries and potential surrogate endpoint for subsequent cardiovascular morbidity and mortality used in previous clinical trials of vitamin supplements. Short-term intervention studies of lycopene supplements are limited, having explored mechanisms through which lycopene or its readily absorbable food sources may increase plasma lycopene or induce changes in other relevant biochemical markers impacting the subsequent risk of coronary heart disease. Ateronon is a lycopene supplement developed with the understanding that the potential clinical effectiveness of lycopene is impacted by its bioavailability. A single daily 7 mg tablet of Ateronon provides more bioavailable lycopene than diet alone, is absorbed efficiently, and completely inhibits the atherogenic lipid oxidation processes in subjects. Clinical studies suggest that short-term treatment with Ateronon among those with coronary heart disease leads to favorable reductions in lipid levels, lipoprotein oxidation, blood pressure, and Rose-Blackburn scores. Therefore, we will conduct a randomized, double-blind, placebo-controlled clinical trial of 7 mg Ateronon taken daily for 1 year among 200 patients aged ≥50 years with stable coronary heart disease. This clinical trial is a collaborative effort between the Division of Preventive Medicine and the Vascular Medicine Program in the Division of Cardiology. Our primary aim is whether taking Ateronon for 1 year is associated with favorable changes in carotid IMT. Secondary aims expand to whether Ateronon leads to favorable 1-year changes in coronary biomarkers related to oxidative stress and endothelial dysfunction; blood pressure; plasma carotenoids; AtheroAbzyme levels; and other traditional coronary biomarkers. This clinical trial of Ateronon seeks to improve our understanding of various mechanisms through which Ateronon, a concentrated and highly bioavailable form of lycopene, may reduce the risk of developing coronary heart disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Ateronon

7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily

Group Type EXPERIMENTAL

Ateronon

Intervention Type DRUG

7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily

Placebo

placebo dietary supplement supplied as one capsule taken daily

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ateronon

7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Brigham and Women's Hospital Cardiology Clinic patients with history of coronary heart disease occurring at least 6 months ago:

* history of myocardial infarction (MI) confirmed by medical records AND/OR
* history of percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG)
* Compliance during run-in as demonstrated by taking at least 66% of study medications
* Ability and willingness to complete questionnaires concerning medical history, concomitant medication use, coronary heart disease risk factors, potential adverse events, and diet

Exclusion Criteria

* History of carotid stent, carotid endarterectomy, or carotid artery surgery
* History of diagnosed congestive heart failure meeting New York Association Functional Classification III or IV criteria
* Any initiation or change in statin use or other lipid-lowering treatment within 3 months of randomization
* Lactose intolerance
* Allergies to whey protein
* Allergies to soy protein
* History of active cancer diagnosis (except non-melanoma skin cancer) within last 3 years
* Life expectancy \< 1 year
* Women who are pregnant, nursing, or intend pregnancy during the period of treatment
* Plan to relocate out of Boston area within the next year
* Inability to provide informed consent
* Carotid artery occlusion or dissection at baseline carotid IMT assessment

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No